AZZ Inc. provides hot-dip galvanizing and coil coating solutions in North America. It offers metal finishing solutions for corrosion protection, including hot-dip galvanizing, spin galvanizing, powder coating, anodizing, and plating to steel fabrication and other industries, as well as to fabricators or manufacturers that provide services to the transmission and distribution, bridge and highway, petrochemical, and general industrial markets; and original equipment manufacturers. It also provides aesthetic and corrosion protective coatings and related value-added services for steel and aluminum coil primarily serving the construction; appliance; heating, ventilation, and air conditioning; container; transportation; and other end markets. The company was incorporated in 1956 and is headquartered in Fort Worth, Texas.

AZZ Inc.

In a report released today, from Goldman Sachs maintained a Buy rating on Azzas 2154 SA, with a price target of BRL35.00. The word on The Street in...

Goldman Sachs Keeps Their Buy Rating on Azzas 2154 SA (AZZA3)

Analysts are intrested in these 5 stocks: ( ($CTXR) ), ( ($AMT) ), ( ($JAZZ) ), ( ($CTMX) ) and ( ($FATE) ). Here is a breakdown of their recent


CTXR, AMT, JAZZ, CTMX, FATE Trending With Analysts

An announcement from Addtech AB Class B ( ($SE:ADDT.B) ) is now available. Addtech reported modest top-line growth but strong profitability for the...

Addtech boosts margins and cash flow as acquisitions fuel profitable growth

The latest update is out from AZZ ( ($AZZ) ). On May 7, 2026, AZZ Inc. executed a Seventh Amendment to its existing credit agreement with Wells Far...

AZZ Extends Revolving Credit Facility, Lowers Borrowing Costs

Jazz Pharmaceuticals (($JAZZ)) has held its Q1 earnings call. Read on for the main highlights of the call. Jazz Pharmaceuticals’ latest earnings ca...

Jazz Pharmaceuticals Signals Confidence After Record Quarter

In a report released today, from Raymond James maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $239.00. In addition to Raym...

Raymond James Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Jazz Pharmaceuticals (JAZZ), Dianthus Therapeutics...

Analysts Conflicted on These Healthcare Names: Jazz Pharmaceuticals (JAZZ), Dianthus Therapeutics (DNTH) and Waters (WAT)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Jazz Pharmaceuticals (JAZZ), uniQure (QURE) and Su...

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ), uniQure (QURE) and Surgery Partners (SGRY)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on DENTSPLY SIRONA (XRAY) and Jazz Pharmaceuticals (J...

Analysts Have Conflicting Sentiments on These Healthcare Companies: DENTSPLY SIRONA (XRAY) and Jazz Pharmaceuticals (JAZZ)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Jazz Pharmaceuticals (JAZZ) and SOPHiA GENETICS (SOP...

Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (JAZZ) and SOPHiA GENETICS (SOPH)

TD Cowen analyst Joseph Thome maintained a Buy rating on Jazz Pharmaceuticals today and set a price target of $220.00. Thome covers the Healthcare ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AZZ	$141.50	+2.61%	192.21K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AZZ	$141.50	+2.6%	192.21K
3
4
5
6

AZZ

AZZ

Get AZZ Inc. Data in Excel

Get AZZ Inc. Data in Excel